Caitlyn Wege of Moodoos Investments on Selecting Pre-Seed Companies, Investing from a Family Office, and Neurodiversity

Picture of by David Paul

by David Paul

Related Blogs

Caitlyn Wege of Moodoos Investments on Selecting Pre-Seed Companies, Investing from a Family Office, and Neurodiversity

Today I am talking to Caitlyn Wege of Moodoos Investments, an early stage family office of the Wege family. Caitlyn is a very active angel investor who is known for being first check in for dynamic ground breaking pre-seed companies. You can watch/listen to the podcast YouTube, Apple, or Spotify.

Caitlin is the Executive Chair at Contract Pharmaceuticals Limited and its sister company, Glasshouse Pharmaceuticals. She serves on the board of Neuralace Medical and Pumpspotting Inc. In addition to her corporate leadership roles, she is a partner at MooDoos Investments. This private family-owned investment fund invests in early-stage companies throughout the US and Canada. MooDoos is industry agnostic and invests in several industries, including life sciences, manufacturing, and education technology.

Caitlin is also the President of NuFund Venture Group. NuFund is one of the largest Angel networks in the US. She is also a Trustee, finance committee member, and Chair of the Governance Committee for the Wege Foundation, an environmentally-focused family foundation based in Grand Rapids, Michigan, a board member of The Ecology Center in Orange County and serves as a mentor and advisory board member for the ZIP Launchpad, the business accelerator at San Diego State University. Caitlin is passionate about fostering entrepreneurial and investor education and learning.

What You’ll Learn:

  • Family Office Workflow

  • Team Work

  • Strategies and Investment Thesis

  • Changes in the Industry and Adjustments

  • How to Choose a Pre-Revenue/Pre-Product Company

  • Angel Community

  • Angel Fund vs. Traditional Angel Investing

  • Neurodiversity

Favorite Quote:

“Seed Investors understand that you can invest in an “A” product in a “B” team and it just won’t survive, but investing in an “A” team with a “B” product that “A” team can turn into an “A” product very easily.”

Subscribe to my Ramblings...

I get up early, like really early—truly, at an unfathomable hour. As part of my morning ritual, I engage in expressive writing to bring clarity to the labyrinth of my thoughts. Delving into topics encompassing startups, investing, and personal growth. People seem to like it.